BioArctic (BIOA-B.ST) Stock Analysis & AI Equity Report

Biotechnology SEK Explore free reports

BioArctic (BIOA-B.ST) overview

BioArctic (BIOA-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, BioArctic reported revenue of SEK 1,999m and operating profit of SEK 1,368m; the year-end share price was 310.80 SEK and market capitalisation was SEK 27,510m. BioArctic is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get BioArctic's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueSEK 1,967mFY 2025
Share price310.80 SEKFY 2025 year end
RevenueSEK 1,999mFY 2025
Operating profitSEK 1,368mFY 2025
Net earningsSEK 1,022mFY 2025
Market capitalisationSEK 27,510mFY 2025 year end

Figures updated on 2026-07-27. Data will be refreshed during report generation.

About BioArctic

BioArctic AB (publ) is a Swedish research-based biopharma company focused on treatments for neurodegenerative diseases. It develops antibody-based drug candidates for Alzheimer’s disease, Parkinson’s disease and ALS, and its BrainTransporter technology helps deliver medicines across the blood-brain barrier. Value is driven by royalties, partnerships, and license agreements, including Leqembi with Eisai.

Generate the BioArctic report

BioArctic is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for BioArctic and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on BioArctic

Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.